<p>Victrex（倫敦證券交易所代碼：VCT - 獲取免費報告）在週一發佈了季度財報。該公司報告季度每股收益為 17.20 便士，Digital Look Earnings 報道。Victrex 的股本回報率為 6.40%，淨利潤率為 9.50%。該公司季度收入為 1.471 億英鎊。</p>
<p>以下是 Victrex 電話會議的主要要點：</p>
<ul>
<li><strong>Victrex 上半年的收入增長了 1%</strong>，達到 1.471 億英鎊，得益於強勁的第二季度和 6% 的銷量增長，但定價和產品組合抵消了一部分收益。</li>
<li><strong>盈利能力減弱</strong>，基礎税前利潤下降 18%，至 1900 萬英鎊，毛利率從 44.1% 降至 41.7%，主要由於價格壓力、產品組合、貨幣因素和醫療銷售疲軟。</li>
<li><strong>現金生成保持穩健</strong>，自由現金流為 2200 萬英鎊，現金轉換率為 109%，淨債務為可控的 0.65 倍 EBITDA。</li>
<li>公司在中國製造工廠記錄了 <strong>6060 萬英鎊的非現金減值</strong>，因為發現一個生產步驟限制了原定 1500 噸的產能。管理層強調這是一個運營問題，而非需求問題，中國的需求依然強勁。</li>
<li><strong>管理層正在採取積極的重組措施</strong>，包括全球員工減少 10%、新的分散運營模式和產品組合簡化，並計劃在 9 月舉行資本市場日以詳細説明戰略和中期盈利改善計劃。</li>
</ul>
<h2>Victrex 價格表現</h2>
<p>LON VCT 的股票週一開盤價為 581 便士。該公司的市值為 5.0619 億英鎊，市盈率為 18.27，市盈增長比率為 1.92，貝塔值為 0.75。Victrex 的 52 周低點為 515 便士，52 周高點為 882 便士。該公司的債務與股本比率為 11.30，速動比率為 1.99，流動比率為 3.01。該股票的 50 日移動平均線為 612.46 便士，200 日移動平均線為 644.88 便士。</p>
<h2>華爾街分析師預測增長</h2>
<p>VCT 已成為幾份研究報告的主題。摩根大通將 Victrex 的目標價從 725 便士下調至 625 便士，並在 3 月 18 日的研究報告中對該股票給予 “買入” 評級。Canaccord Genuity Group 在 4 月 13 日的研究報告中重申了 “買入” 評級，並對 Victrex 的股票設定了 725 便士的目標價。兩位股票研究分析師對該股票給予 “買入” 評級，三位分析師則給予 “持有” 評級。根據 MarketBeat 的數據，Victrex 的平均評級為 “持有”，共識目標價為 750 便士。</p>
<p><strong>查看我們最新的 VCT 股票分析</strong></p>
<h2>關於 Victrex</h2>
<p>（獲取免費報告）</p>
<p>Victrex plc 通過其子公司在全球範圍內從事聚合物解決方案的製造和銷售。該公司通過可持續解決方案和醫療兩個部門運營。它開發 PEEK 和 PAEK 基聚合物解決方案，以及半成品和成品。該公司還為醫療設備製造商提供專業解決方案；銷售熱塑性聚合物；為能源和工業、VAR、汽車、航空航天和電子市場提供可持續解決方案；並從事貿易活動。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Victrex</li>
<li>超越 NVIDIA：強勁勢頭的 AI 相關股票</li>
<li>量子財報季正在加速——關注兩大主要參與者</li>
<li>Flutter 在財報後看到提振，FanDuel 顯示覆蘇跡象</li>
<li>3 只醫療保健股票將受益於這項重大法案</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PUxPTiZTeW1ib2w9VkNU?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PUxPTiZTeW1ib2w9VkNU"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Victrex 嗎？</h2>
<p>在考慮 Victrex 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Victrex 並不在名單上。</p>
<p>雖然 Victrex 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Victrex（倫敦證券交易所代碼：VCT）報告了本季度每股收益為 17.20 便士，收入為 1.471 億英鎊。該公司在上半年經歷了 1% 的收入增長，但盈利能力下降，税前基礎利潤下降 18%，至 1900 萬英鎊。其中國工廠記錄了 6060 萬英鎊的非現金減值。管理層正在實施重組措施，包括全球員工人數減少 10%。分析師的評級意見不一，普遍目標價為 750 便士，目前評級為 “持有”</p>

<p>Victrex (LON:VCT - Get Free Report) posted its quarterly earnings data on Monday. The company reported GBX 17.20 EPS for the quarter, Digital Look Earnings reports. Victrex had a return on equity of 6.40% and a net margin of 9.50%.The firm had revenue of £147.10 million for the quarter.</p>
<div class="lb-trans"><p>Victrex（倫敦證券交易所代碼：VCT - 獲取免費報告）在週一發佈了季度財報。該公司報告季度每股收益為 17.20 便士，Digital Look Earnings 報道。Victrex 的股本回報率為 6.40%，淨利潤率為 9.50%。該公司季度收入為 1.471 億英鎊。</p>
</div><p>Here are the key takeaways from Victrex's conference call:</p>
<div class="lb-trans"><p>以下是 Victrex 電話會議的主要要點：</p>
</div><ul>
<li><strong>Victrex’s H1 revenue rose 1%</strong> to GBP 147.1 million, helped by a strong Q2 and 6% volume growth, but pricing and mix offset some of the benefit.</li>
<li><strong>Profitability weakened</strong>, with underlying PBT down 18% to GBP 19 million and gross margin falling to 41.7% from 44.1% due to price pressure, mix, currency, and softer medical sales.</li>
<li><strong>Cash generation remained solid</strong>, with free cash flow of GBP 22 million, cash conversion of 109%, and net debt at a manageable 0.65x EBITDA.</li>
<li>The company recorded a <strong>GBP 60.6 million non-cash impairment</strong> on its China manufacturing plant after concluding one production step is limiting capacity versus the original 1,500-ton nameplate. Management emphasized this is an operational issue, not a demand issue, and China demand remains strong.</li>
<li><strong>Management is taking aggressive restructuring actions</strong>, including a 10% global headcount reduction, a new decentralized operating model, and portfolio simplification, with a September capital markets day planned to detail the strategy and medium-term profit improvement plan.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Victrex 上半年的收入增長了 1%</strong>，達到 1.471 億英鎊，得益於強勁的第二季度和 6% 的銷量增長，但定價和產品組合抵消了一部分收益。</li>
<li><strong>盈利能力減弱</strong>，基礎税前利潤下降 18%，至 1900 萬英鎊，毛利率從 44.1% 降至 41.7%，主要由於價格壓力、產品組合、貨幣因素和醫療銷售疲軟。</li>
<li><strong>現金生成保持穩健</strong>，自由現金流為 2200 萬英鎊，現金轉換率為 109%，淨債務為可控的 0.65 倍 EBITDA。</li>
<li>公司在中國製造工廠記錄了 <strong>6060 萬英鎊的非現金減值</strong>，因為發現一個生產步驟限制了原定 1500 噸的產能。管理層強調這是一個運營問題，而非需求問題，中國的需求依然強勁。</li>
<li><strong>管理層正在採取積極的重組措施</strong>，包括全球員工減少 10%、新的分散運營模式和產品組合簡化，並計劃在 9 月舉行資本市場日以詳細説明戰略和中期盈利改善計劃。</li>
</ul>
</div><h2>Victrex Price Performance</h2>
<div class="lb-trans"><h2>Victrex 價格表現</h2>
</div><p>Shares of LON VCT opened at GBX 581 on Monday. The stock has a market cap of £506.19 million, a PE ratio of 18.27, a price-to-earnings-growth ratio of 1.92 and a beta of 0.75. Victrex has a fifty-two week low of GBX 515 and a fifty-two week high of GBX 882. The company has a debt-to-equity ratio of 11.30, a quick ratio of 1.99 and a current ratio of 3.01. The stock has a fifty day moving average of GBX 612.46 and a 200-day moving average of GBX 644.88.</p>
<div class="lb-trans"><p>LON VCT 的股票週一開盤價為 581 便士。該公司的市值為 5.0619 億英鎊，市盈率為 18.27，市盈增長比率為 1.92，貝塔值為 0.75。Victrex 的 52 周低點為 515 便士，52 周高點為 882 便士。該公司的債務與股本比率為 11.30，速動比率為 1.99，流動比率為 3.01。該股票的 50 日移動平均線為 612.46 便士，200 日移動平均線為 644.88 便士。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>VCT has been the topic of several research reports. JPMorgan Chase &amp; Co. lowered their target price on Victrex from GBX 725 to GBX 625 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, March 18th. Canaccord Genuity Group reiterated a &#34;buy&#34; rating and issued a GBX 725 price target on shares of Victrex in a research report on Monday, April 13th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, Victrex has an average rating of &#34;Hold&#34; and a consensus price target of GBX 750.</p>
<div class="lb-trans"><p>VCT 已成為幾份研究報告的主題。摩根大通將 Victrex 的目標價從 725 便士下調至 625 便士，並在 3 月 18 日的研究報告中對該股票給予 “買入” 評級。Canaccord Genuity Group 在 4 月 13 日的研究報告中重申了 “買入” 評級，並對 Victrex 的股票設定了 725 便士的目標價。兩位股票研究分析師對該股票給予 “買入” 評級，三位分析師則給予 “持有” 評級。根據 MarketBeat 的數據，Victrex 的平均評級為 “持有”，共識目標價為 750 便士。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on VCT</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 VCT 股票分析</strong></p>
</div><h2>About Victrex</h2>
<div class="lb-trans"><h2>關於 Victrex</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Victrex plc, through its subsidiaries, engages in the manufacture and sale of polymer solutions worldwide. The company operates through two segments, Sustainable Solutions and Medical. It develops PEEK and PAEK based polymer solutions, and semi-finished and finished parts. The company also provides specialist solutions for medical device manufacturers; sells thermoplastic polymers; sustainable solutions for energy and industrial, VAR, automotive, aerospace, and electronics markets; and engages in trading activities.</p>
<div class="lb-trans"><p>Victrex plc 通過其子公司在全球範圍內從事聚合物解決方案的製造和銷售。該公司通過可持續解決方案和醫療兩個部門運營。它開發 PEEK 和 PAEK 基聚合物解決方案，以及半成品和成品。該公司還為醫療設備製造商提供專業解決方案；銷售熱塑性聚合物；為能源和工業、VAR、汽車、航空航天和電子市場提供可持續解決方案；並從事貿易活動。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Victrex</li>
<li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li>
<li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li>
<li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li>
<li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Victrex</li>
<li>超越 NVIDIA：強勁勢頭的 AI 相關股票</li>
<li>量子財報季正在加速——關注兩大主要參與者</li>
<li>Flutter 在財報後看到提振，FanDuel 顯示覆蘇跡象</li>
<li>3 只醫療保健股票將受益於這項重大法案</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PUxPTiZTeW1ib2w9VkNU" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=LON&amp;Symbol=VCT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Victrex Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Victrex 嗎？</h2>
</div><p>Before you consider Victrex, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Victrex 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Victrex wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Victrex 並不在名單上。</p>
</div><p>While Victrex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Victrex 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Victrex（倫敦證券交易所代碼：VCT）公佈了收益結果